In trading on Thursday, shares of Fortuna Silver Mines Inc (FSM) entered into oversold territory, changing hands as low as $4.37 per share. We define oversold territory using the Relative Strength Index, or RSI, which is a technical analysis indicator used to measure momentum on a scale of zero to 100. A stock is considered to be oversold if the RSI reading falls below 30.In the case of Fortuna Silver Mines Inc, the RSI reading has hit 28.2 — by comparison, the universe of metals and mining stocks covered by Metals Channel currently has an average RSI of 45.2, the RSI of Spot Gold is at 55.0, and the RSI of Spot Silver is presently 39.3. A bullish investor could look at FSM's 28.2 reading as a sign that the recent heavy selling is in the process of exhausting itself, and begin to look for entry point opportunities on the buy side. Looking at a chart of one year performance (below), FSM's low point in its 52 week range is $4.37 per share, with $9.75 as the 52 week high point — that compares with a last trade of $4.42. Fortuna Silver Mines Inc shares are currently trading off about 3.6% on the day. According to the ETF Finder at ETF Channel, FSM makes up 2.11% of the Junior Gold Miners ETF ( GDXJ) which is trading lower by about 1.2% on the day Thursday.
More from Stocks
Badgley Mischka Designers on How Tariffs are Impacting the Fashion Industry
Mark Badgley and James Mischka discuss how tariffs are impacting handbags.
Tesla, CVS, Google and the Federal Reserve - 5 Things You Must Know
U.S. stock futures point to a weaker start for Wall Street on Wednesday, though there are increasing signs of tangible progress in U.S.-China trade talks; CVS and Avis report earnings; Elon Musk says Tesla will have the technology in place for a self-driving car by the end of the year.
Jim Cramer's Worried About Amazon and Apple and Their 'Achilles Heel' Statuses
Jim Cramer explains why he's worried about two of the FANG names. Hint: Divorce and Huawei.
Teva Slips After 'Pay-For-Delay' Settlement with US Federal Trade Commission
Teva Pharmaceuticals shares were indicated lower in pre-market trading Wednesday after the drugmaker reached a settlement with the Federal Trade Commission over allegations it delayed the release of generic medicines through agreements with pharmaceutical rivals.